Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II consolidation 90Y-ibritumomab tiuxetan after R-PECC in relapsed/refractory aggressive B-cell NHL
2006-007083-28Phase 2Active
- Sponsor
- HOVON
- Start
- Mar 2008
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in mature B-cell lymphoma, sponsored by HOVON. Primary endpoint: Feasibility and safety of 90Y-ibritumomab tiuxetan consolidation. Started Mar 2008; status: active.
02
Drugs
ibritumomab tiuxetan
03
Conditions
mature B-cell lymphoma
Beyond the preview
Go deeper on 2006-007083-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-007083-28.